A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Paraganglioma; Pheochromocytoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2017 According to a Progenics Pharmaceuticals media release, the company will present final results from this trial at the North American Neuroendocrine Tumor Society (NANETS) 2017 Annual Symposium.
    • 06 Sep 2017 Planned End Date changed from 1 Jun 2021 to 1 Feb 2021.
    • 31 Aug 2017 Results published in a Progenics Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top